Get the Stockscreener App
79.80
2.47%
-2.08
Tarsus Pharmaceuticals Inc stock is traded at $79.80, with a volume of 464.08K.
It is down -2.47% in the last 24 hours and up +0.52% over the past month.
Tarsus Pharmaceuticals Inc is a commercial-stage biopharmaceutical company focused on the development and commercialization of therapeutics, starting with eye care. The company is focused on the development and commercialization of first-in-class therapeutic candidates to provide treatment for ophthalmic conditions. The company's candidate XDEMVY is a novel investigational eye drop to treat blepharitis caused by the infestation of Demodex mites, referred to as Demodex blepharitis.
See More
Previous Close:
$81.88
Open:
$81.38
24h Volume:
464.08K
Relative Volume:
0.85
Market Cap:
$3.39B
Revenue:
$17.39M
Net Income/Loss:
$-135.89M
P/E Ratio:
-17.20
EPS:
-4.64
Net Cash Flow:
$-123.00M
1W Performance:
-2.35%
1M Performance:
+0.52%
6M Performance:
+97.42%
1Y Performance:
+44.80%
1-Day Range:
$79.42
$83.92
1-Week Range:
$79.42
$83.94
52-Week Range:
$38.51
$85.25
Tarsus Pharmaceuticals Inc Stock (TARS) Company Profile
Name
Tarsus Pharmaceuticals Inc
Sector
Industry
Phone
(949) 409-9820
Address
15440 LAGUNA CANYON ROAD, IRVINE
Compare TARS with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
TARS
Tarsus Pharmaceuticals Inc
|
79.89 | 3.48B | 17.39M | -135.89M | -123.00M | -4.64 |
|
VRTX
Vertex Pharmaceuticals Inc
|
452.79 | 115.03B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
774.65 | 81.12B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
398.40 | 52.54B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
840.72 | 51.78B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
175.51 | 37.12B | 447.02M | -1.18B | -906.14M | -6.1812 |
Tarsus Pharmaceuticals Inc Stock (TARS) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-09-25 | Initiated | Barclays | Overweight |
| Nov-20-25 | Initiated | Mizuho | Outperform |
| Jun-02-25 | Resumed | Oppenheimer | Outperform |
| May-27-25 | Resumed | H.C. Wainwright | Buy |
| Nov-20-23 | Initiated | Goldman | Neutral |
| Jul-18-23 | Initiated | William Blair | Outperform |
| May-18-23 | Initiated | Guggenheim | Buy |
| Aug-01-22 | Initiated | Barclays | Overweight |
| Dec-21-21 | Initiated | H.C. Wainwright | Buy |
| Nov-23-21 | Initiated | Oppenheimer | Outperform |
| Nov-10-20 | Initiated | BofA Securities | Buy |
| Nov-10-20 | Initiated | Jefferies | Buy |
| Nov-10-20 | Initiated | Ladenburg Thalmann | Buy |
| Nov-10-20 | Initiated | Raymond James | Strong Buy |
View All
Tarsus Pharmaceuticals Inc Stock (TARS) Latest News
Tarsus Pharmaceuticals (NASDAQ:TARS) CEO Bobak Azamian Sells 6,000 Shares - MarketBeat
Tarsus Pharmaceuticals Insider Sold Shares Worth $495,089, According to a Recent SEC Filing - marketscreener.com
Will Tarsus Pharmaceuticals Inc. stock split attract more investorsDividend Cut Warnings & Low Risk Investment Plans - bollywoodhelpline.com
Tarsus to Participate at the Bank of America 2023 Healthcare Conference - 富途牛牛
240,020 Shares in Tarsus Pharmaceuticals, Inc. $TARS Purchased by Capricorn Fund Managers Ltd - MarketBeat
Tarsus Pharmaceuticals Earnings Notes - Trefis
Market Sentiment Around Loss-Making Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) - simplywall.st
Will Tarsus Pharmaceuticals Inc. stock see PE expansionTake Profit Strategies & Free Hedging Tactics for Volatile Markets - Bollywood Helpline
Tarsus Pharmaceuticals (TARS) Stock Analysis Report | Ratings, Financials & Performance - Benzinga
Technical Reactions to TARS Trends in Macro Strategies - Stock Traders Daily
Why Tarsus Pharmaceuticals Inc. stock could rally in 2025July 2025 Opening Moves & Weekly Breakout Watchlists - Улправда
Can Tarsus Pharmaceuticals Inc. stock double in next 5 yearsJuly 2025 Retail & AI Enhanced Trading Signals - Улправда
Will Tarsus Pharmaceuticals Inc. stock outperform tech sector in 2025Market Movers & AI Powered Buy/Sell Recommendations - DonanımHaber
Can Tarsus Pharmaceuticals Inc. stock hit record highs againJuly 2025 Trade Ideas & AI Driven Price Predictions - DonanımHaber
Why analysts upgrade Tarsus Pharmaceuticals Inc. stock2025 Technical Overview & Fast Gaining Stock Reports - Улправда
Insider Sell: Dianne Whitfield Sells 7,397 Shares of Tarsus Phar - GuruFocus
Tarsus Pharmaceuticals (NASDAQ:TARS) Insider Dianne Whitfield Sells 7,397 Shares - MarketBeat
Tarsus Pharmaceuticals Insider Sold Shares Worth $592,500, According to a Recent SEC Filing - marketscreener.com
Tarsus Pharmaceuticals (TARS) COO discloses stock gifts and 79,183-share stake - Stock Titan
Assenagon Asset Management S.A. Has $74.17 Million Stock Holdings in Tarsus Pharmaceuticals, Inc. $TARS - MarketBeat
Officer Whitfield Files To Sell 7,397 Of Tarsus Pharmaceuticals Inc [TARS] - TradingView — Track All Markets
Squarepoint Ops LLC Boosts Position in Tarsus Pharmaceuticals, Inc. $TARS - MarketBeat
TFG Asset Management GP Ltd Grows Stake in Tarsus Pharmaceuticals, Inc. $TARS - MarketBeat
Trading the Move, Not the Narrative: (TARS) Edition - Stock Traders Daily
Tarsus Pharmaceuticals (NASDAQ:TARS) Upgraded at Barclays - MarketBeat
Tarsus Pharmaceuticals chief medical officer talks AI in eye care - Healthcare Brew
Barclays Initiates Coverage on Tarsus Pharmaceuticals (TARS) wit - GuruFocus
Jump Financial LLC Purchases 188,317 Shares of Tarsus Pharmaceuticals, Inc. $TARS - MarketBeat
Norges Bank Acquires Shares of 471,354 Tarsus Pharmaceuticals, Inc. $TARS - MarketBeat
Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) Given Average Rating of "Moderate Buy" by Analysts - MarketBeat
Tarsus Pharmaceuticals (NASDAQ:TARS) Sets New 12-Month HighHere's What Happened - MarketBeat
Tarsus Pharmaceuticals stock hits all-time high at 83.67 USD - Investing.com
Tarsus Pharmaceuticals stock hits all-time high at 83.67 USD By Investing.com - Investing.com Australia
Tarsus Pharmaceuticals Leads Six-Month Stock Performance with 85.5% Return - Markets Mojo
Quantbot Technologies LP Purchases 24,319 Shares of Tarsus Pharmaceuticals, Inc. $TARS - MarketBeat
Can Tarsus Pharmaceuticals Stock Still Offer Value After Its 48% 2025 Rally? - Yahoo Finance
Tarsus Pharmaceuticals (TARS): Revisiting Valuation After a Strong Multi‑Year Share Price Run - Sahm
Quadrature Capital Ltd Invests $588,000 in Tarsus Pharmaceuticals, Inc. $TARS - MarketBeat
(TARS) Volatility Zones as Tactical Triggers - news.stocktradersdaily.com
Virtus Investment Advisers LLC Buys 3,827 Shares of Tarsus Pharmaceuticals, Inc. $TARS - MarketBeat
Tarsus Pharmaceuticals, Inc. $TARS Shares Bought by Prudential Financial Inc. - MarketBeat
Geode Capital Management LLC Raises Position in Tarsus Pharmaceuticals, Inc. $TARS - MarketBeat
Magnetar Financial LLC Takes $596,000 Position in Tarsus Pharmaceuticals, Inc. $TARS - MarketBeat
Tarsus Pharmaceuticals (NASDAQ:TARS) Hits New 1-Year HighHere's What Happened - MarketBeat
Tarsus to Participate in Upcoming Investor Conference - The Manila Times
Tarsus Pharmaceuticals, Inc.'s (NASDAQ:TARS) Profit Outlook - 富途牛牛
Tarsus Pharmaceuticals, Inc. $TARS Shares Sold by Artisan Partners Limited Partnership - MarketBeat
Will Tarsus Pharmaceuticals Inc. stock maintain dividend yieldMarket Trend Summary & Fast Gain Swing Alerts - newser.com
Tarsus Pharmaceuticals (TARS) Is Up 6.1% After Analyst Upgrades Highlight XDEMVY Sales Momentum - Sahm
Mizuho Begins Coverage on Tarsus Pharmaceuticals (NASDAQ:TARS) - MarketBeat
Tarsus Pharmaceuticals: Xdemvy Momentum Continues In Q3 (NASDAQ:TARS) - Seeking Alpha
Tarsus Pharmaceuticals Inc Stock (TARS) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.28%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):